{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:02:50Z","timestamp":1789552970629,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.canlet.2011.07.002","type":"journal-article","created":{"date-parts":[[2011,7,24]],"date-time":"2011-07-24T02:27:18Z","timestamp":1311474438000},"page":"207-215","source":"Crossref","is-referenced-by-count":68,"title":["Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: A beneficial strategy to combat non-small cell lung cancer"],"prefix":"10.1016","volume":"310","author":[{"given":"Yaara","family":"Gorzalczany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Gilad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Amihai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Hammel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Sagi-Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Merimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2011.07.002_b0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.patbio.2008.10.002","article-title":"The increasing role of amphiregulin in non-small cell lung cancer","volume":"57","author":"Busser","year":"2009","journal-title":"Pathol Biol."},{"key":"10.1016\/j.canlet.2011.07.002_b0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer."},{"key":"10.1016\/j.canlet.2011.07.002_b0015","first-page":"771","article-title":"Prognostic impact of p53 pro72 homozygous genotype in non-small cell lung cancer patients.","volume":"19","author":"Boldrini","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2011.07.002_b0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00001813-200606000-00001","article-title":"Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway","volume":"17","author":"Smolewski","year":"2006","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.canlet.2011.07.002_b0025","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2011.07.002_b0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11523-008-0101-x","article-title":"Imatinib in the treatment of solid tumours","volume":"4","author":"Duffaud","year":"2009","journal-title":"Target. Oncol."},{"key":"10.1016\/j.canlet.2011.07.002_b0035","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.1158\/0008-5472.CAN-05-1083","article-title":"Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells","author":"Paglin","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.07.002_b0040","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/sj.leu.2404606","article-title":"The anticancer drug imatinib induces cellular autophagy","volume":"21","author":"Ertmer","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.07.002_b0045","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/j.1349-7006.2008.00932.x","volume":"99","author":"Mishima","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2011.07.002_b0050","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/cdd.2009.33","article-title":"Life and death partners: apoptosis, autophagy and the cross-talk between them","volume":"16","author":"Eisenberg-Lerner","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2011.07.002_b0055","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s10495-008-0307-5","article-title":"The paradox of autophagy and its implication in cancer etiology and therapy","volume":"14","author":"Eisenberg-Lerner","year":"2009","journal-title":"Apoptosis"},{"key":"10.1016\/j.canlet.2011.07.002_b0060","first-page":"225","article-title":"Molecular impacts of rapamycin based drug combinations; characterization of the molecular consequences of applying the mTOR inhibitor rapamycin with either gemcitabine or imatinib mesylate on human leiomyosarcoma","volume":"31","author":"Merimsky","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2011.07.002_b0065","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/13.7.604","article-title":"The histochemical demonstration of monoamine oxidase activity by coupled peroxidatic oxidation","volume":"13","author":"Graham","year":"1965","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.canlet.2011.07.002_b0070","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin-receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2011.07.002_b0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: From growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2011.07.002_b0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"mTOR and cancer: many loops in one pathway","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.canlet.2011.07.002_b0085","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","article-title":"Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non, small-cell lung, pancreatic, colon, and breast tumors","volume":"5","author":"Buck","year":"2006","journal-title":"Mol. Cancer Therap."},{"key":"10.1016\/j.canlet.2011.07.002_b0090","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1158\/1541-7786.MCR-09-0507","article-title":"Targeting epidermal growth factor receptor, associated signaling pathways in non-small cell lung cancer cells: implication in radiation response","volume":"8","author":"Choi","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2011.07.002_b0095","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.1158\/0008-5472.CAN-05-1083","article-title":"Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells","volume":"65","author":"Paglin","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.07.002_b0100","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/annonc\/mdp060","article-title":"Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors","volume":"20","author":"Soria","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2011.07.002_b0105","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.bjc.6603366","article-title":"Treatment with imatinib in NSCLC is associated with decrease of phosphorylated PDGF[beta] and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation","volume":"95","author":"Vlahovic","year":"2006","journal-title":"Br. J. Cancer."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511003983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511003983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T03:57:05Z","timestamp":1560398225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383511003983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0304383511003983"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2011.07.002","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}